Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw unusually-strong trading volume on Thursday. Approximately 369,784 shares were traded during trading, an increase of 278% from the average daily volume of 97,781 shares. The stock last traded at $29.9580 and had previously closed at $29.70.

Analyst Ratings Changes

NBTX has been the subject of several recent research reports. Guggenheim started coverage on shares of Nanobiotix in a research report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, October 15th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Nanobiotix presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.67.

Nanobiotix Price Performance

The company has a fifty day moving average price of $31.76 and a two-hundred day moving average price of $33.84.

About Nanobiotix

Nanobiotix is a biotechnology company developing nanoparticle-based therapies designed to improve the effectiveness of radiotherapy in cancer treatment. The company’s technology uses hafnium oxide nanoparticles that are injected directly into a tumor and activated by ionizing radiation, with the goal of increasing energy deposition within cancer cells while limiting exposure to surrounding tissue.

Nanobiotix’s lead product candidate, NBTXR3, is being evaluated in clinical studies across several cancer types, including locally advanced head and neck cancer and other solid tumors.